trial · primary record
Ritlecitinib 100 mg
Alopecia Areata
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 336 |
| Primary completion | 2028-04-26 |
| Primary endpoint | Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placebo |
| Registry ID | NCT07733765 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:52.416Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07733765
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.